Jan 06, 2022 / 01:00PM GMT
Keyur Parekh - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Good morning, Happy New Year, and thank you all for joining us. My name is Keyur Parekh, and I cover the European biopharma names for Goldman Sachs. It's my pleasure to welcome Emma Walmsley, CEO of Glaxo for this conversation. Emma, thank you so much for taking your time and for joining us. We really appreciate it.
Emma N. Walmsley - GlaxoSmithKline plc - CEO & Director
Well, it's wonderful to be here, a very happy new year to you, Keyur, on behalf of GSK. I'll get you to move on from the Glaxo words. And a hugely happy new year to everybody who's either joining the video or listening later. I hope it's a healthy, happy and impactful one for you all.
Questions and Answers:
Keyur Parekh - Goldman Sachs Group, Inc., Research Division - Equity AnalystEmma, I don't want to spend a lot of time talking through Glaxo -- GSK and kind of the various moving parts of the business. But if we kind of start at a 30,000-foot industry level, lots
Trustpilot
